Anti-retroviral Protease Inhibitors Market Outlook:
Anti-retroviral Protease Inhibitors Market size was valued at USD 5.9 billion in 2025 and is projected to reach USD 10.7 billion by the end of 2035, rising at a CAGR of 6.9% during the forecast period, i.e., from 2026 to 2035. In 2026, the industry size of anti-retroviral protease inhibitors is evaluated at USD 6.3 billion.
The global market is growing due to the increasing occurrence of HIV, AIDS, and positive innovations in combination therapies, and increasing access to advanced procedures and treatment in developing countries. According to a report by UNAIDS in July 2023, in 2022, 39.0 million people were living with HIV, and 29.8 million people were getting antiretroviral therapy. Besides, globally, 4,000 young women and girls become infected with HIV every week, with women and girls especially in sub-Saharan Africa still disproportionately affected. Due to this continuously increasing burden, the demand for anti-retroviral protease inhibitors is expanding rapidly.
Focus on improved patient outcomes initiated several funding activities for HIV responses in developing countries. According to a report by UNAIDS in July 2023, due to support and investment for stopping AIDS in children, in 2022, treatment was offered to about 82% of pregnant and breastfeeding women with HIV globally. Furthermore, major strides have been taken in low-cost antiretroviral drug manufacturing for greater access in low-income parts of the world. Another export of newer drugs with more investments in research and development promised greater efficacy and tolerability. Furthermore, the government, NGOs, and drug companies collaborate in promoting further innovation and improved linkages to life-saving interventions.
